Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(04): 330-332
DOI: 10.4103/0971-5851.125262
CASE REPORT

Cisplatin induced paroxysmal supraventricular tachycardia

Waseem Raja
Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
,
M Hussain Mir
Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
,
Imtiyaz Dar
Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
,
Muzamil Ahmad Banday
Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
,
Irfan Ahmad
Department of Cardiology, Sheri Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Cisplatin or cis-diamminedichloroplatinum (CDDP) is the first member of a class of platinum-containing anti-cancer drugs that act by binding to and causing cross-linking of deoxyribonucleic acid, which ultimately triggers apoptosis. Cisplatin has a broad-spectrum antineoplastic activity against various types of human tumors. Unfortunately, the optimal usefulness of Cisplatin is limited secondary to its dose related toxicity especially nephrotoxicity. Cisplatin chemotherapy is also associated with cardiotoxic effects that may range from silent arrhythmias to heart failure and even sudden cardiac death. These effects are more pronounced when cisplatin is combined with other cardiotoxic drugs. Here, we report a case of patient of cancer lung who developed paroxysmal supraventricular tachycardia following administration of Cisplatin. A brief review of the literature follows.

Keywords

Cisplatin - lung cancer - paroxysmal supraventricular tachycardia


Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Peyrone M. On the action of ammonia on platinous. Ann Pharm Chem 1844;51:1-29.
  • 2 Carpenter DP. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, NJ: Princeton University Press.
  • 3 Ferroni P, Della-Morte D, Palmirotta R, McClendon M, Testa G, Abete P, et al. Platinum-based compounds and risk for cardiovascular toxicity in the elderly: Role of the antioxidants in chemoprevention. Rejuvenation Res 2011;14:293-308.
  • 4 Zumkley H, Bertram HP, Preusser P, Kellinghaus H, Straub C, Vetter H. Renal excretion of magnesium and trace elements during cisplatin treatment. Clin Nephrol 1982;17:254-7.
  • 5 Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979;90:929-31.
  • 6 Yavas Ö, Aytemir K, Celik Ý. The prevalence of silent arrhythmia in patients receiving cisplatin-based chemotherapy. Turk J Cancer 2008;38:1.
  • 7 Altena R, Hummel YM, Nuver J, Smit AJ, Lefrandt JD, de Boer RA, et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 2011;22:2286-93.
  • 8 Wang J, He D, Zhang Q, Han Y, Jin S, Qi F. Resveratrol protects against cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother Radiopharm 2009;24:675-80.
  • 9 El-Awady el-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 2011;650:335-41.